Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
SAGE Therapeutics (SAGE)
NASDAQ:SAGE
SAGE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.62 - $23.22
Previous CloseN/A
Volume244.47K
Average Volume (3M)2.42M
Market Cap
$441.43M
Enterprise Value-$118.95M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.99
Next Earnings
May 06, 2025EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.60
Shares Outstanding61,480,946
10 Day Avg. Volume1,728,277
30 Day Avg. Volume2,417,330
Standard Deviation0.16
R-Squared0.10
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.70
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.74
Enterprise Value/Ebitda0.29
Forecast
1Y Price Target
$8.38Price Target Upside17.20% Upside
Rating ConsensusHold
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Market CoverageCoverage for Zurzuvae continues to improve, with over 95% of commercial and Medicaid lives covered or having a path to coverage.
Product DemandDemand growth for Zurzuvae was significantly stronger, showing a 21% increase quarter over quarter.
Strategic ExpansionBiogen and Sage remain committed to the product and have expanded their sales force teams, planning to increase targeted marketing efforts with DTC and social media campaigns to increase disease awareness and drive growth for Zurzuvae.
Bears Say
Financial Performance4Q24 missed expectations on the top and bottom line, largely due to Zurzuvae channel dynamics and one-time restructuring expenses.
Revenue ConcernsSage reported somewhat weaker sales performance in 4Q with the collaboration revenue of Zurzuvae being much lower than estimated.
Strategic UncertaintySAGE decided not to accept Biogen's unsolicited takeover approach, which adds uncertainty to the company's strategic direction.
---
Ownership Overview
0.72% Insiders
18.60% Mutual Funds
26.23% Other Institutional Investors
42.99% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAGE FAQ
What was SAGE Therapeutics’s price range in the past 12 months?
SAGE Therapeutics lowest stock price was $4.62 and its highest was $23.22 in the past 12 months.
What is SAGE Therapeutics’s market cap?
SAGE Therapeutics’s market cap is $441.43M.
When is SAGE Therapeutics’s upcoming earnings report date?
SAGE Therapeutics’s upcoming earnings report date is May 06, 2025 which is in 74 days.
How were SAGE Therapeutics’s earnings last quarter?
SAGE Therapeutics released its earnings results on Feb 11, 2025. The company reported -$1.56 earnings per share for the quarter, missing the consensus estimate of -$1.483 by -$0.077.
Is SAGE Therapeutics overvalued?
According to Wall Street analysts SAGE Therapeutics’s price is currently Undervalued.
Does SAGE Therapeutics pay dividends?
SAGE Therapeutics does not currently pay dividends.
What is SAGE Therapeutics’s EPS estimate?
SAGE Therapeutics’s EPS estimate is -0.99.
How many shares outstanding does SAGE Therapeutics have?
SAGE Therapeutics has 61,480,946 shares outstanding.
What happened to SAGE Therapeutics’s price movement after its last earnings report?
SAGE Therapeutics reported an EPS of -$1.56 in its last earnings report, missing expectations of -$1.483. Following the earnings report the stock price went down -0.417%.
Which hedge fund is a major shareholder of SAGE Therapeutics?
Currently, no hedge funds are holding shares in SAGE
---
SAGE Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.38 (17.20% Upside)
$8.38 (17.20% Upside)
Blogger Sentiment
Bullish
SAGE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 432.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.74%
12-Months-Change
Fundamentals
Return on Equity
-63.37%
Trailing 12-Months
Asset Growth
-37.98%
Trailing 12-Months
Company Description
SAGE Therapeutics
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
---
SAGE Company Deck
---
SAGE Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects positive momentum with the successful launch and strong adoption of ZURZUVAE in the market, supported by effective commercial strategies and comprehensive coverage. However, challenges remain with revenue growth not keeping pace with demand and significant net losses impacting financial health.Read More>---
SAGE Stock 12 Month Forecast
Average Price Target
$8.38
▲(17.20% Upside)
Technical Analysis
Best Analysts Covering SAGE
1 Year
1 Year Success Rate
9/20 ratings generated profit
1 Year Average Return
-3.71%
reiterated a sell rating 3 months ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of -3.71% per trade.
---